A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallate [(-)-EGCG]

被引:113
作者
Lam, WH
Kazi, A
Kuhn, DJ
Chow, LMC
Chan, ASC
Dou, QP
Chan, TH [1 ]
机构
[1] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China
[2] Hong Kong Polytech Univ, Open Lab Chiral Technol, Inst Mol Technol Drug Discovery & Synth, Hong Kong, Hong Kong, Peoples R China
[3] Wayne State Univ, Prevent Program, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA
[4] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA
关键词
D O I
10.1016/j.bmc.2004.08.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Green tea has been shown to have many biological effects, including effects on metabolism, angiogenesis, oxidation, and cell proliferation. Unfortunately, the most abundant green tea polyphenol (-)-epigallocatechin gallate or (-)-EGCG is very unstable in neutral or alkaline medium. This instability leads to a low bioavailability. In an attempt to enhance the stability of (-)-EGCG, we introduced peracetate protection groups on the reactive hydroxyls of (-)-EGCG (noted in text as 1). HPLC analysis shows that the protected (-)-EGCG analog is six times more stable than natural (-)-EGCG under slightly alkaline conditions. A series of bioassays show that 1 has no inhibitory activity against a purified 20S proteasome in vitro, but exhibits increased proteasome-inhibitory activity in intact leukemic cells over natural (-)-EGCG, indicating an intercellular conversion. Inhibition of cellular proteasome activity by 1 is associated with induction of cell death. Therefore, our results indicate that the protected analog 1 may function as a prodrug of the green tea polyphenol proteasome inhibitor (-)-EGCG. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5587 / 5593
页数:7
相关论文
共 31 条
[21]  
Pianetti S, 2002, CANCER RES, V62, P652
[22]   PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization [J].
Shin, I ;
Yakes, FM ;
Rojo, F ;
Shin, NY ;
Bakin, AV ;
Baselga, J ;
Arteaga, CL .
NATURE MEDICINE, 2002, 8 (10) :1145-1152
[23]   Docking studies and model development of tea polyphenol proteasome inhibitors: Applications to rational drug design [J].
Smith, DM ;
Daniel, KG ;
Wang, ZG ;
Guida, WC ;
Chan, TH ;
Dou, QP .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2004, 54 (01) :58-70
[24]   Synthetic analogs of green tea polyphenols as proteasome inhibitors [J].
Smith, DM ;
Wang, ZG ;
Kazi, A ;
Li, LH ;
Chan, TH ;
Dou, QP .
MOLECULAR MEDICINE, 2002, 8 (07) :382-392
[25]  
SUEMATSU S, 1992, J JPN SOC FOOD SCI, V39, P178
[26]   Analysis of (-)-epigallocatechin gallate in human serum obtained after ingesting green tea [J].
Unno, T ;
Kondo, K ;
Itakura, H ;
Takeo, T .
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 1996, 60 (12) :2066-2068
[27]   The PI3K-PDK1 connection: more than just a road to PKB [J].
Vanhaesebroeck, B ;
Alessi, DR .
BIOCHEMICAL JOURNAL, 2000, 346 (pt 3) :561-576
[28]   Study of the green polyphenols catechin-3-gallate (CG) and epicatechin-3-gallate (ECG) as proteasome inhibitors [J].
Wan, SB ;
Chen, D ;
Dou, QP ;
Chan, TH .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (13) :3521-3527
[29]   Inhibition of carcinogenesis by tea [J].
Yang, CS ;
Maliakal, P ;
Meng, XF .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2002, 42 :25-54
[30]  
YANG CS, 1993, J NATL CANCER I, V85, P1049